<code id='7C60E29B47'></code><style id='7C60E29B47'></style>
    • <acronym id='7C60E29B47'></acronym>
      <center id='7C60E29B47'><center id='7C60E29B47'><tfoot id='7C60E29B47'></tfoot></center><abbr id='7C60E29B47'><dir id='7C60E29B47'><tfoot id='7C60E29B47'></tfoot><noframes id='7C60E29B47'>

    • <optgroup id='7C60E29B47'><strike id='7C60E29B47'><sup id='7C60E29B47'></sup></strike><code id='7C60E29B47'></code></optgroup>
        1. <b id='7C60E29B47'><label id='7C60E29B47'><select id='7C60E29B47'><dt id='7C60E29B47'><span id='7C60E29B47'></span></dt></select></label></b><u id='7C60E29B47'></u>
          <i id='7C60E29B47'><strike id='7C60E29B47'><tt id='7C60E29B47'><pre id='7C60E29B47'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:entertainment    Page View:549
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In